Overall response rate of 22% in Phase IIb for CytRx's aldoxorubicin
This article was originally published in Scrip
CytRx's targeted chemotherapy drug aldoxorubicin generated a response in 22% of soft tissue sarcoma patients treated with the company's targeted chemotherapy drug versus no responses in doxorubicin-treated Phase IIb clinical trial participants, but the rates of stable disease were equal in both arms of the trial.
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.